TY - JOUR
T1 - Japanese guidelines for atopic dermatitis 2020
AU - Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association
AU - Katoh, Norito
AU - Ohya, Yukihiro
AU - Ikeda, Masanori
AU - Ebihara, Tamotsu
AU - Katayama, Ichiro
AU - Saeki, Hidehisa
AU - Shimojo, Naoki
AU - Tanaka, Akio
AU - Nakahara, Takeshi
AU - Nagao, Mizuho
AU - Hide, Michihiro
AU - Fujita, Yuji
AU - Fujisawa, Takao
AU - Futamura, Masaki
AU - Masuda, Koji
AU - Murota, Hiroyuki
AU - Yamamoto-Hanada, Kiwako
N1 - Funding Information:
Each committee member declared the status of potential conflict of interest (COI) based on the standards of conflict of interest stipulated by their respective institute of affiliation (or The Japanese Association of Medical Sciences COI management guidelines at http://jams.med.or.jp/guideline/coi_guidelines.pdf [in Japanese]). The costs to develop these guidelines have been supported by: grants for research from the Japanese Dermatological Association (JDA) ; Grant-in-Aid for Scientific Research from the MHLW (as a Research Project on Measures for Intractable Diseases [Research on Allergic Disease and Immunology]). Committee members have not received any remuneration for developing the guidelines or attending related meetings. There has been no intervention by the JDA or Japanese Society of Allergology (JSA) that may influence the contents of the guidelines. To avoid any influence by potential COIs, if any, on the guidelines, all recommendations were determined based on consensus voting, rather than on individual opinion, in reference to the opinions of the representatives of the JDA and JSA (public comment).
Funding Information:
Each committee member declared the status of potential conflict of interest (COI) based on the standards of conflict of interest stipulated by their respective institute of affiliation (or The Japanese Association of Medical Sciences COI management guidelines at http://jams.med.or.jp/guideline/coi_guidelines.pdf [in Japanese]). The costs to develop these guidelines have been supported by: grants for research from the Japanese Dermatological Association (JDA); Grant-in-Aid for Scientific Research from the MHLW (as a Research Project on Measures for Intractable Diseases [Research on Allergic Disease and Immunology]). Committee members have not received any remuneration for developing the guidelines or attending related meetings. There has been no intervention by the JDA or Japanese Society of Allergology (JSA) that may influence the contents of the guidelines. To avoid any influence by potential COIs, if any, on the guidelines, all recommendations were determined based on consensus voting, rather than on individual opinion, in reference to the opinions of the representatives of the JDA and JSA (public comment).
Publisher Copyright:
© 2020 Japanese Society of Allergology
PY - 2020/7
Y1 - 2020/7
N2 - Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
AB - Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85082808195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082808195&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2020.02.006
DO - 10.1016/j.alit.2020.02.006
M3 - Review article
C2 - 32265116
AN - SCOPUS:85082808195
SN - 1323-8930
VL - 69
SP - 356
EP - 369
JO - Allergology International
JF - Allergology International
IS - 3
ER -